神经内分泌肿瘤骨转移的姑息性放射治疗
该研究回顾性分析了2011至2018年间一家机构686例神经内分泌肿瘤(NEN)患者记录,识别出28例(4.1%)因61处骨骼相关事件(SRE)接受放疗。所有患者均有骨痛,55/61处(90%)放疗后疼痛改善,中位疼痛复发或进展时间3.5个月;
要点
- NEN骨转移放疗后90%的病例疼痛改善,中位疼痛进展时间3.5个月。
- 单次与分次放疗、姑息与消融剂量在疼痛进展和体能状态变化上无差异。
核心结论
- 尽管该NEN队列中多数病例从放疗中获益,仍需进一步研究放疗在疼痛性骨转移治疗中的应用。
研究设计与样本
- 回顾性研究,回顾2011至2018年间一家机构686例NEN患者记录,识别28例(4.1%)因61处SRE接受放疗的患者。
- 主要终点为放疗后患者报告的疼痛评分变化。
主要发现
- 所有28例患者均有骨痛。
- 61处中55处(90%)放疗后疼痛改善,中位疼痛复发或进展时间3.5个月。
- 年龄、放疗期间化疗或放疗部位与疼痛进展时间、体能状态变化及疼痛改善程度无差异。
临床怎么用
- 对于NEN骨转移相关疼痛,放疗可考虑作为姑息治疗手段,单次与分次方案均可选择。
局限性
- 回顾性研究,样本量小(28例患者,61处SRE),来自单中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bone metastases are reported in 10% to 12% of patients with neuroendocrine neoplasms (NENs) and can lead to pain and skeletal-related events (SREs), resulting in diminished quality of life and functional status. In other solid tumors with bone metastases, radiation therapy (RT) is an established treatment approach for SREs, yet few data are available in NENs historically considered to be radioresistant. We hypothesize that RT is effective for pain and other SREs in NENs and aimed to delineate any differences in pain palliation and time until progression of pain between different fractionation and dosing schedules of RT. METHODS AND MATERIALS: We retrospectively reviewed 686 records of patients with NENs treated at the institution between 2011 and 2018 and identified 28 (4.1%) patients treated with RT for 61 cases of SREs. The primary endpoint was change in patient reported pain scores after RT. RESULTS: All 28 patients experienced bone pain. Nineteen sites were treated with a single fraction (doses of 800-1800 cGy) and 42 sites with fractionated regimens (doses of 900-3750 cGy over 3-15 fractions). In 55 of 61 cases (90%), patients experienced improvement in pain after RT. The median time to recurrence or progression of pain was 3.5 months. Significant differences were found between primary site and change in performance status (P = .024), sex, and reported magnitude of pain score decrease after RT (P = .025). There were no differences in the time to the progression of pain, change in performance status, and degree of improvement in pain based on age, chemotherapy received during RT, or radiation site. Outcomes were similar for patients who received single-fraction versus fractionated regimens (P = .545) and between those receiving palliative versus ablative RT regimens (P = .812). CONCLUSIONS: Although the majority of cases in this NEN cohort benefited from RT, additional studies on the use of RT in the treatment of painful bone metastases are warranted.
引用
- Guan M, He I, Luu M, et al. Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. Adv Radiat Oncol. 2019. PMID: 31360808. doi:10.1016/j.adro.2019.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。